RGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Repligen Corp (RGEN) is not a strong buy for a beginner, long-term investor at this moment. Despite positive revenue growth, the significant decline in net income and EPS, insider selling, and bearish technical indicators suggest caution. The stock's current price trend and lack of strong trading signals do not present a compelling entry point.
The MACD is positive and expanding, indicating some bullish momentum, but the RSI is neutral at 41.246, showing no clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below the pivot level of 120.038, with key support at 113.724 and resistance at 126.352. Overall, the technical indicators suggest a bearish trend.
Revenue increased by 18.12% YoY in Q4 2025, and gross margin improved by 9.45% YoY. Analysts maintain positive ratings with price targets significantly above the current price, suggesting potential long-term upside.
Net income dropped by -139.23% YoY, and EPS fell by -138.33% YoY, indicating profitability challenges. Insider selling increased by 143.49% over the last month, which could signal a lack of confidence from insiders. No recent news or event-driven catalysts to drive near-term momentum.
In Q4 2025, revenue grew to $197.91M (up 18.12% YoY), but net income fell to $13.29M (-139.23% YoY), and EPS dropped to $0.23 (-138.33% YoY). Gross margin improved to 52.46% (up 9.45% YoY), reflecting better operational efficiency despite profitability challenges.
Analysts remain positive with ratings such as Outperform, Buy, and Overweight. However, price targets have been lowered recently (e.g., Evercore ISI to $170 from $180, UBS to $195 from $200), reflecting tempered expectations. Analysts highlight potential upside due to conservative guidance and strong Q1 start.
